Literature DB >> 10926203

Selective induction of the monocyte-attracting chemokines MCP-1 and IP-10 in vesicular stomatitis virus-infected human monocytes.

D Bussfeld1, M Nain, P Hofmann, D Gemsa, H Sprenger.   

Abstract

It is characteristic of viral infections that monocytes/macrophages and lymphocytes infiltrate infected tissue, and neutrophils are absent. CC and non-ELR CXC chemokines predominantly attract mononuclear leukocytes, whereas the ELR motif-expressing CXC chemokines primarily act on neutrophils. To investigate the general role of chemokines in viral diseases, we determined their release and expression patterns after infection of human monocytes with vesicular stomatitis virus (VSV). Human monocytes were productively infected by VSV. Surprisingly, VSV did not induce the release of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6. In contrast, we found a strong induction of the CC chemokine monocyte chemotactic protein-1 (MCP-1) and the non-ELR CXC chemokine interferon-gamma (IFN-gamma) inducible protein-10 (IP-10) by VSV on the gene and protein level. The expression and release of the neutrophil chemoattractants IL-8 and growth-related oncogene-alpha (GRO-alpha) remained unaffected after VSV infection. Our results indicate that the typical monocyte and lymphocyte-dominated leukocyte infiltration of virus-infected tissue is based on a selective induction of mononuclear leukocyte-attracting chemokines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926203     DOI: 10.1089/107999000414781

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

Review 1.  Molecular pathogenesis of Salmonella enterica serotype typhimurium-induced diarrhea.

Authors:  Shuping Zhang; Robert A Kingsley; Renato L Santos; Helene Andrews-Polymenis; Manuela Raffatellu; Josely Figueiredo; Jairo Nunes; Renee M Tsolis; L Garry Adams; Andreas J Bäumler
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

Review 2.  The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus.

Authors:  Lisi Amsler; Marieke Verweij; Victor R DeFilippis
Journal:  J Mol Biol       Date:  2013-09-05       Impact factor: 5.469

3.  Gene expression contributing to recruitment of circulating cells in response to vesicular stomatitis virus infection of the CNS.

Authors:  Derek D C Ireland; Carol Shoshkes Reiss
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

4.  Rabies virus stimulates nitric oxide production and CXC chemokine ligand 10 expression in macrophages through activation of extracellular signal-regulated kinases 1 and 2.

Authors:  Kazuo Nakamichi; Satoshi Inoue; Tomohiko Takasaki; Kinjiro Morimoto; Ichiro Kurane
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

Authors:  Angela Huttner; Christophe Combescure; Stéphane Grillet; Mariëlle C Haks; Edwin Quinten; Christine Modoux; Selidji Todagbe Agnandji; Jessica Brosnahan; Julie-Anne Dayer; Ali M Harandi; Laurent Kaiser; Donata Medaglini; Tom Monath; Pascale Roux-Lombard; Peter G Kremsner; Tom H M Ottenhoff; Claire-Anne Siegrist
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

Review 6.  Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.

Authors:  Yihong Yao; Brandon W Higgs; Laura Richman; Barbara White; Bahija Jallal
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

7.  The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12.

Authors:  Béatrice Vanbervliet; Nathalie Bendriss-Vermare; Catherine Massacrier; Bernhard Homey; Odette de Bouteiller; Francine Brière; Giorgio Trinchieri; Christophe Caux
Journal:  J Exp Med       Date:  2003-09-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.